UBS/CALL/ELI LILLY & CO/850.001/0.01/20.09.24 | Real-time Bid/Ask 11:51:08 28/05/2024 BST | ||
| 0.41 CHF / 0.43 CHF | 0.00% |
|
| Current month | +27.27% | ||
| 1 month | +68.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 0.42 | -4.55% |
| 23/05/24 | 0.44 | +12.82% |
| 22/05/24 | 0.39 | -2.50% |
| 21/05/24 | 0.4 | +37.93% |
Delayed Quote Swiss Exchange
Last update May 24, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYHPU | |
| ISIN | CH1327379934 |
| Date issued | 19/02/2024 |
| Strike | 850 $ |
| Maturity | 20/09/2024 (116 Days) |
| Parity | 100 : 1 |
| Emission price | 0.48 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.56 CHF |
|---|---|
| Lowest since issue | 0.22 CHF |
| Spread | 0.02 CHF |
| Spread % | 4.65% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Warrants
- LLYHPU Warrant
